Brokerages Set Regulus Therapeutics Inc. (RGLS) Price Target at $2.90

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have been assigned a consensus rating of “Hold” from the nine brokerages that are covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $2.90.

Several equities analysts have commented on RGLS shares. Zacks Investment Research raised shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.00 price target for the company in a research report on Wednesday, July 12th. Chardan Capital decreased their price target on shares of Regulus Therapeutics from $5.00 to $2.50 and set a “buy” rating for the company in a research report on Tuesday, June 13th. BMO Capital Markets reissued a “hold” rating on shares of Regulus Therapeutics in a research report on Monday, May 15th. Wedbush reissued an “ourperform” rating and issued a $6.00 price target on shares of Regulus Therapeutics in a research report on Tuesday, June 13th. Finally, ValuEngine cut shares of Regulus Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd.

ILLEGAL ACTIVITY WARNING: “Brokerages Set Regulus Therapeutics Inc. (RGLS) Price Target at $2.90” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.com-unik.info/2017/07/17/brokerages-set-regulus-therapeutics-inc-rgls-price-target-at-2-90.html.

Shares of Regulus Therapeutics (RGLS) traded down 7.4563% during trading on Friday, reaching $0.9532. 972,869 shares of the company were exchanged. Regulus Therapeutics has a 1-year low of $0.86 and a 1-year high of $4.25. The firm has a 50-day moving average price of $1.27 and a 200-day moving average price of $1.58. The stock’s market capitalization is $50.69 million.

Large investors have recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL boosted its stake in Regulus Therapeutics by 131.5% in the first quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 61,373 shares during the period. South Dakota Investment Council boosted its stake in Regulus Therapeutics by 16.3% in the first quarter. South Dakota Investment Council now owns 1,327,058 shares of the biopharmaceutical company’s stock valued at $2,190,000 after buying an additional 186,130 shares during the period. Wedbush Securities Inc. boosted its stake in Regulus Therapeutics by 106.8% in the first quarter. Wedbush Securities Inc. now owns 180,921 shares of the biopharmaceutical company’s stock valued at $299,000 after buying an additional 93,420 shares during the period. Wells Fargo & Company MN boosted its stake in Regulus Therapeutics by 13.5% in the first quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock valued at $1,291,000 after buying an additional 93,295 shares during the period. Finally, Teachers Advisors LLC boosted its stake in Regulus Therapeutics by 15.7% in the fourth quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock valued at $163,000 after buying an additional 9,804 shares during the period. 38.56% of the stock is owned by institutional investors and hedge funds.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Analyst Recommendations for Regulus Therapeutics (NASDAQ:RGLS)

What are top analysts saying about Regulus Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Regulus Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit